Research Papers:
Long-term effects of sitagliptin in patients with type 2 diabetes mellitus and hypertension: results from the PROLOGUE study
PDF | HTML | How to cite
Metrics: PDF 1198 views | HTML 1979 views | ?
Abstract
Ziliang Ye1,3,*, Hui Li3,*, Haili Lu2,3, Qiang Su1 and Lang Li1
1Department of Cardiology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
2Department of Orthodontics, The Affiliated Dental Hospital of Guangxi Medical University, Nanning, Guangxi, China
3Guangxi Medical University, Nanning, Guangxi, China
*These authors have contributed equally to this work
Correspondence to:
Lang Li, email: [email protected]
Keywords: dipeptidyl peptidase 4 inhibitors; sitagliptin; type 2 diabetes; hypertension; PROLOGUE study
Received: June 03, 2017 Accepted: November 20, 2017 Published: December 06, 2017
ABSTRACT
Background: The effects of sitagliptin in patients with type 2 diabetes mellitus and hypertension are unclear. Therefore, we evaluated the long-term effects of sitagliptin in those patients.
Methods: In the PROLOGUE study, 365 patients were diagnosed as type 2 diabetes mellitus and hypertension, and 189 patients in the sitagliptin group, 176 patients in the conventional group. Fasting blood glucose (FBG), HbA1c, systolic pressure (SP), diastolic pressure (DP), serum urea nitrogen (BUN) and serum creatinine (SCR) were measured at the beginning of the study and after 12 and 24 months of treatment.
Results: FBS and HbA1c levels were not significantly decreased after treatment [12 months: OR: -3.1, 95% CI (-11.3, 5.0); OR: 0.1, 95% CI (0.0, 0.3); 24 months: OR: -0.1, 95% CI (-9.1, 8.8); OR: 0.1, 95% CI (0.0, 0.3), respectively]. BP and DP levels were not significantly decreased after treatment (12 months: OR: 0.9, 95% CI (-2.8, 4.6); OR: 0.6, 95% CI (-2.0, 3.2); 24 months: OR: -0.5, 95% CI (-4.2, 3.1); OR: -1.6, 95% CI (-41, 0.9), respectively]. Furthermore, BUN and SCR levels were not significantly decreased after treatment (12 months: OR: 0.0, 95%CI (-1.2, 1.2); OR: 0.0, 95% CI (-0.1, 0.0); 24 months: OR: 0.4, 95% CI (-1.0, 1.8); OR: -80.8, 95% CI (-201.3, 39.8), respectively]. After adjusting for confounding factors, our results did not change.
Conclusions: In our study, there was no evidence that treatment with sitagliptin can improve FBS, BP, DP, BUN or SCR in patients with type 2 diabetes mellitus and hypertension.
Trial Registration: University Hospital Medical Information Network Clinical Trials Registry UMIN000004490.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 22959